Carrier-Free Cur/DTX@ICG Ternary Nanoparticles for Suppressing Lung Metastasis in Triple-Negative Breast Cancer.

Authors

Shupeng Han, Meichen Zheng, Jingjing Zhang, Jianmin Chen, Feifei An, Yu Ren, Mingsong Shi

Published in

Small (Weinheim an der Bergstrasse, Germany). Pages e76217. Oct 13, 2026. Epub Oct 13, 2026.

Abstract

Chemotherapy for advanced breast cancer may promote metastatic progression through inflammatory responses. To address this challenge, we developed carrier-free Cur/DTX@ICG nanoparticles via molecular co-assembly, achieving a high drug-loading capacity of 66.7%. This theranostic platform integrates docetaxel, curcumin, and indocyanine green for chemotherapy, anti-inflammatory chemosensitization, and fluorescence imaging. Cur/DTX@ICG effectively inhibited triple-negative breast cancer (TNBC) cell proliferation and migration in vitro. In vivo, it suppressed subcutaneous tumor growth by 74.5% and achieved 77.1% inhibition of postoperative lung metastasis while prolonging survival. Mechanistically, Cur/DTX@ICG attenuated chemotherapy-associated inflammatory responses by reducing serum TNF-α, IL-6, and IL-1β levels, suppressing nuclear factor-κB (NF-κB) activation, and partially reversing epithelial-mesenchymal transition (EMT) progression. These findings suggest that Cur/DTX@ICG represents a promising carrier-free strategy for suppressing inflammation-associated metastatic progression in TNBC.

PMID:
42865332
Bibliographic data and abstract were imported from PubMed on 13 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.